title: Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy.
abstract: OBJECTIVE
  We conducted this study to evaluate the efficacy and safety of adjuvant chemotherapy using taxane plus carboplatin (CBDCA) for high-risk stage IB-IIB patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy.
  
  
  METHODS
  Thirty-seven patients were eligible. Pelvic lymph node involvement and/or parametrial invasion were defined as high-risk factors. The patients were treated with 6 cycles of paclitaxel (PTX, 175 mg/m(2)) or docetaxel (DTX, 60 mg/m(2)) followed by CBDCA (area under the curve, 6) every 3 weeks. The primary end point was 2-year progression-free survival (PFS) rate, and the secondary end point was the assessment of adverse events.
  
  
  RESULTS
  Twenty-two patients received PTX/CBDCA (TC) chemotherapy, and the remaining 15 patients underwent DTX/CBDCA (DC) chemotherapy. The 2-year PFS rate was 62.1% (95% confidence interval, 44.6%-75.5%). Patients receiving DC chemotherapy showed a better 2-year PFS rate compared to those with TC chemotherapy, but the difference was not statistically significant (80.0% vs 50.0%, P = 0.1400). The most common grade 3/4 adverse events were hematologic toxicities, which were generally well tolerable. Nonhematologic toxicity was generally mild.
  
  
  CONCLUSIONS
  Taxane and CBDCA combination chemotherapy, especially DC chemotherapy, may be one of the useful adjuvant treatments for high-risk stage IB-IIB patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy.
authors.affiliation: *Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago City; †Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata; ‡Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai; §Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi; ∥Department of Obstetrics and Gynecology, Jikei University School of Medicine, Minato; ¶Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume; and #Department of Obstetrics and Gynecology, Matsue City Hospital, Matsue, Japan.
authors.forename: Seiya
authors.initials: S
authors.lastname: Sato
authors.forename: Muneaki
authors.initials: M
authors.lastname: Shimada
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ohta
authors.forename: Takanobu
authors.initials: T
authors.lastname: Kojimahara
authors.forename: Hideki
authors.initials: H
authors.lastname: Tokunaga
authors.forename: Tadao
authors.initials: T
authors.lastname: Takano
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tanabe
authors.forename: Shin
authors.initials: S
authors.lastname: Nishio
authors.forename: Junzo
authors.initials: J
authors.lastname: Kigawa
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D018196:Carcinoma, Adenosquamous / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane; D016190:Carboplatin